0RDB.L
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Industry
Medical - Pharmaceuticals
IPO Date
2016-12-15
Stock Exchange
LSE
Ticker
0RDB.L
According to Oryzon Genomics S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -36.85. This represents a change of -141.98% compared to the average of 87.78 of the last 4 quarters.
The mean historical PE Ratio of Oryzon Genomics S.A. over the last ten years is -38.85. The current -36.85 PE Ratio has changed 9.39% with respect to the historical average. Over the past ten years (40 quarters), 0RDB.L's PE Ratio was at its highest in in the June 2025 quarter at 423.35. The PE Ratio was at its lowest in in the June 2020 quarter at -164.78.
Average
-38.85
Median
-31.62
Minimum
-99.76
Maximum
0
Discovering the peaks and valleys of Oryzon Genomics S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 315.54%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -99.76
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -24.59 | -32.62% |
| 2023 | -36.49 | 11.10% |
| 2022 | -32.85 | 8.08% |
| 2021 | -30.39 | -44.04% |
| 2020 | -54.31 | -Infinity% |
| 2019 | 0 | -100.00% |
| 2018 | -70.90 | 315.54% |
| 2017 | -17.06 | -22.91% |
| 2016 | -22.13 | -77.81% |
| 2015 | -99.76 | -606.68% |
The current PE Ratio of Oryzon Genomics S.A. (0RDB.L) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-31.31
5-year avg
-35.73
10-year avg
-38.85
Oryzon Genomics S.A.’s PE Ratio is less than Transgene S.A. (-3.30), less than LNA Santé S.A. (11.56), less than Formycon AG (-2.59), less than Medios AG (19.62), less than Stratec SE (19.30), less than AB Science S.A. (-8.19), less than Oriola Oyj (-8.03), less than Boiron S.A. (27.57), less than Bastide Le Confort Médical S.A. (111.10), less than Guerbet S.A. (23.45),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.30 | N/A | |
| 11.56 | N/A | |
| -2.59 | N/A | |
| 19.62 | N/A | |
| 19.30 | N/A | |
| -8.19 | N/A | |
| -8.03 | N/A | |
| 27.57 | N/A | |
| 111.10 | N/A | |
| 23.45 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oryzon Genomics S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oryzon Genomics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oryzon Genomics S.A.'s PE Ratio?
How is the PE Ratio calculated for Oryzon Genomics S.A. (0RDB.L)?
What is the highest PE Ratio for Oryzon Genomics S.A. (0RDB.L)?
What is the 3-year average PE Ratio for Oryzon Genomics S.A. (0RDB.L)?
What is the 5-year average PE Ratio for Oryzon Genomics S.A. (0RDB.L)?
How does the current PE Ratio for Oryzon Genomics S.A. (0RDB.L) compare to its historical average?